Telegraph Hill Partners Raises $310M Fund for New Investments in Life Science and Healthcare Companies

Telegraph Hill Partners Raises $310M Fund for New Investments in Life Science 
and Healthcare Companies 
SAN FRANCISCO, CA -- (Marketwired) -- 07/29/13 --  Telegraph Hill
Partners (THP), a leading venture capital and growth equity firm
dedicated exclusively to life science and healthcare investing, has
had its final closing on a new $310 million fund and plans to use it
to help finance innovative enterprises on the verge of expansion. The
fund, THP III, is Telegraph Hill Partners' largest since the firm was
formed in 2001. 
"Capital commitments exceeded our target and represent a new record
for THP," stated Matt Mackowski, Chairman of THP. "We are delighted
by the participation of our existing limited partners and are
gratified to have added several new investors to the fund. We also
thank the leaders of our portfolio companies because their
exceptional performance was a key component in enabling our firm to
reach this significant milestone."  
Consistent with its previous funds, THP III will invest in companies
with advanced technologies that have already demonstrated organic
revenue growth and a superior business model. Areas of focus include
life science tools, reagents, specialty chemistries, medical
technology, medical devices, healthcare IT, healthcare services,
agriculture and animal health.  
THP utilizes an extensive range of investment structures to
effectively address the capital needs of each company. These
structures range from venture capital to growth equity to buyouts and
secondary acquisitions. With the new fund, Telegraph Hill Partners
expects to invest in 10-12 innovative, high-growth companies across
the United States. THP's previous investments include Althea
Technologies (acquired by Ajinomoto Co.), Ambion, (acquired by
Applied Biosystems Group), Dharmacon (acquired by ThermoFisher),
NEXUS Biosystems (acquired by Brooks Automation), LDR (based in
Austin, TX) and Vidacare (based in San Antonio, TX). 
Ronald Seubert, President and Chief Executive Officer of RareCyte,
worked with Telegraph Hill Partners when he held the same positions
at Applied Precision, a THP portfolio company that was acquired by GE
Healthcare. "THP was an active partner with us. They provided
strategic guidance and practical advice in many areas that helped us
grow our business, achieve profitability and establish our company as
a leading life sciences instruments business."  
About Telegraph Hill Partners 
Telegraph Hill Partners, founded in 2001 and based in San Francisco,
CA, invests in commercial stage life science, medical technology and
healthcare companies. For more information please see
www.telegraphhillpartners.com.  
For further information: 
Alan Zachary
HDM
312/506-5220
mobile: 708/707-6834
azachary@harrisdmckinney.com 
 
 
Press spacebar to pause and continue. Press esc to stop.